June 23, 2026 05:22 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Italy and I never beg': Meloni fires back at Trump over G7 photo claim | No more 'brother': Stalin's formal birthday greeting to Rahul reflects deepening rift | TMC seeks disqualification of 20 rebel MPs, Abhishek says 'membership should go' | Nara Lokesh pitches Andhra Pradesh as investment hub during Kolkata visit, sets $2.4 trillion economy goal | 'Least restrictive option': Setback for Telegram as Delhi HC backs Centre's ban ahead of NEET-UG re-test | Fortuner torched, BJP leaders burnt alive: Sand mining feud ends in triple murder in Chhattisgarh | 'If Modi is the leader and India is attacked, we'll be there': Trump's strong assurance at G7 | 'Safety of Indian seafarers of utmost importance': PM Modi's strong message to Trump at G7 | Trump says Iran deal 'not final', threatens fresh strikes if Tehran ‘doesn’t behave’ | G7 declares war on global drug cartels, unveils major anti-trafficking plan
COVID-19
Image: PIB

Momentous feat: PM Modi after world's first DNA based anti-COVID-19 vaccine ZyCov-D gets nod

| @indiablooms | Aug 21, 2021, at 04:36 pm

New Delhi/IBNS: Prime Minister Narendra Modi has lauded the scientists after the world's first DNA based anti-COVID-19 vaccine, ZyCov-D, got approval for an emergency use in India.

The Prime Minister tweeted, "India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."

Zydus Cadila Friday received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.

Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.

This three-dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance.

The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.